The Claim
In patients with atherosclerotic cardiovascular disease who are already receiving statin therapy, the addition of evolocumab does not significantly increase the risk of adverse events such as new-onset diabetes or neurocognitive events compared to placebo; the only statistically significant difference observed is a higher incidence of injection-site reactions (2.1% vs 1.6%), indicating that PCSK9 inhibition with evolocumab is safe in the short-to-medium term in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease who are on cholesterol-lowering drugs, adding a drug called evolocumab doesn’t raise their risk of serious side effects like diabetes or memory problems — the only real downside is a slightly higher chance of soreness at the injection site.
See the scientific wording
In patients with atherosclerotic cardiovascular disease on statin therapy, adding evolocumab does not significantly increase the risk of adverse events such as new-onset diabetes or neurocognitive events compared to placebo, with the only significant difference being a higher rate of injection-site reactions (2.1% vs 1.6%), supporting the short-to-medium-term safety of PCSK9 inhibition in this population.
What the research says
1 studyStudy: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
The study looked at whether adding a drug called evolocumab to statins causes more side effects. It found no increase in serious side effects like diabetes or memory problems, just slightly more reactions at the injection site, which supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.